Authors
Quinten Debrabander, Kathryn S Hensley, Christina K Psomas, Wichor Bramer, Tokameh Mahmoudi, Berend J van Welzen, Annelies Verbon, Casper Rokx
Publication date
2023/8/19
Source
Journal of virus eradication
Pages
100342
Publisher
Elsevier
Description
Introduction
Understanding the clinical potency of latency reversing agents (LRAs) on the HIV-1 reservoir is useful to deploy future LRA strategies. This systematic review evaluated the effects of LRAs in human intervention studies.
Methods
A literature search was performed using medical databases focusing on studies with adults living with HIV-1 receiving LRAs. Eligibility criteria required participants from prospective clinical studies, a studied compound hypothesised as LRA, and reactivation or tolerability assessments. Relevant demographical data, LRA reactivation capacity, reservoir size, and adverse events were extracted. A study quality assessment with analysis of bias was performed by RoB-2 and ROBINS-I tools. The primary endpoints were HIV-1 reservoir reactivation after LRA treatment quantified by cell-associated unspliced HIV-1 RNA, and LRA tolerability defined by adverse events. Secondary …
Total citations
2023202417